Oruka Therapeutics
ORKA
21 hedge funds and large institutions have $6.55M invested in Oruka Therapeutics in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 4 closing their positions.
14% more capital invested
Capital invested by funds: $5.75M → $6.55M (+$802K)
0.25% more ownership
Funds ownership: 1.64% → 1.88% (+0.25%)
9% less funds holding
Funds holding: 23 → 21 (-2)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$1.11M |
| 2 |
Renaissance Technologies
New York
|
+$12.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$2.55K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$245 |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$98 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
M
Murchinson
Toronto,
Ontario, Canada
|
-$103K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$27.1K |
| 3 |
NM
Newtyn Management
New York
|
-$26.9K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$22.6K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$3.13K |
ORKA Hedge Fund Activity: Q3 2023 in Review
21 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2023, worth a combined $6.55M — up 14% from $5.75M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of ORKA and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 4 added.
The largest buyer was Western Standard LLC, adding an estimated $1.11M. The largest seller was Murchinson, exiting entirely with an estimated $103K sold.
- 21 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2023, down from 23 in Q2 2023.
- Funds reported $6.55M of Oruka Therapeutics stock for Q3 2023, up 14% quarter-over-quarter.
- 3 funds opened new Oruka Therapeutics positions in Q3 2023 and 4 closed out, a net change of -1 holder.
- The largest Oruka Therapeutics buyer in Q3 2023 was Western Standard LLC, an estimated $1.11M added.
- The largest Oruka Therapeutics seller in Q3 2023 was Murchinson, an estimated $103K sold.
Based on aggregated 13F filings for Q3 2023.